In the last trading session, the share price of AEterna Zentaris Inc. (NASDAQ:AEZS) opened the market again with gap after the news from Wednesday morning, though it seems that further positive effect of the new agreement is not be expected. 
After the initial jump to $1.70, however, AEZS fell back down and closed the market only with a 2.47% increase at $1.66. Trading volume amounted over 860,000 traded shares, which is only about half of the daily average for the past 30 days, signaling that the positive effect of the latest news may have already expired.
That effect was not that strong anyway as on the day of the announcement the trading volume was even smaller, but the stock price seems to be slowly starting to appreciate since it reached a bottom in the beginning of October.
On Wednesday morning, AEZS announced that it had signed an exclusive commercialization and licensing agreement with Hikma Pharmaceuticals PLC (LSE: HIK.L) concerning the registration and marketing of AEZS lead anticancer compound perifosine. The agreement is for Middle East and North Africa region and AEZS is entitled to receive an upfront payment and certain milestone payments for a total of $2 million, as well as royalties on future net sales in those regions.
About two weeks ago, the company also filed its financial results for the quarter ending September 2011, which sounded promising as well. Revenues had increased on an quarter-over-quarter basis from $5.7 million to $9.5 million, while the company also reported a positive net income of $1.1 million as compared to a loss of $9.9 million for the same quarter in 2010.
